Genome-wide analysis links NFATC2 with asparaginase hypersensitivity

Blood

Volumn 126, Issue 1, 2015, Pages 69-75

  Fernandez, Christian A ^a   Smith, Colton ^a   Yang, Wenjian ^a   Mullighan, Charles G ^a   Qu, Chunxu ^a   Larsen, Eric ^b   Bowman, W Paul ^c   Liu, Chengcheng ^a   Ramsey, Laura B ^a   Chang, Tamara ^a   Karol, Seth E ^a   Loh, Mignon L ^d   Raetz, Elizabeth A ^e   Winick, Naomi J ^f   Hunger, Stephen P ^g   Carroll, William L ^h   Jeha, Sima ^a   Pui, Ching Hon ^a   Evans, William E ^a   Devidas, Meenakshi ⁱ   Relling, Mary V ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Maine Children's Cancer Program Scarborough   (United States)

^c Risk Evaluation to Achieve Cardiovascular Health   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; DNA; HLA DRB1 ANTIGEN; ASPARAGINASE; NFATC2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NFAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); DNA MICROARRAY; DRUG HYPERSENSITIVITY; FEMALE; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HAPLOTYPE MAP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NFATC2 GENE; PPP3CA GENE; PRIORITY JOURNAL; PRKCE GENE; PRKCQ GENE; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ADVERSE EFFECTS; ENZYME REPLACEMENT; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; ENZYME REPLACEMENT THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA-DRB1 CHAINS; HUMANS; INFANT; MALE; NFATC TRANSCRIPTION FACTORS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 84937797142     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-628800     Document Type: Article

References (35)

1. Yang L, Boyd K, Kaste SC, Kamdem Kamdem L, Rahija RJ, Relling MV. A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res. 2009;27(2): 169-175.
2. Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood. 2012;119(7):1658-1664.
3. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer. 1976;37(1): 220-228.
4. Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012; 26(11):2303-2309.
5. Fernandez CA, Stewart E, Panetta JC, et al. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol. 2014;73(6):1307-1313.
6. Chen SH, Pei D, Yang W, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010;88(2):191-196.
7. Fernandez CA, Smith C, Yang W, et al. HLA-DRB107:01 is associated with a higher risk of asparaginase allergies. Blood. 2014;124(8): 1266-1276.
8. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18(7):1525-1532.
9. Treviño LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9): 1001-1005.
10. Yang JJ, Cheng C, Devidas M, et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet. 2011;43(3): 237-241.
11. Goya R, Sun MG, Morin RD, et al. SNVMix: predicting single nucleotide variants from nextgeneration sequencing of tumors. Bioinformatics. 2010;26(6):730-736.
12. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153-166.
13. Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45(10):1226-1231.
14. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNAseq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511-515.
15. Zhang W, Dolan ME. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009;15(32):3782-3795.
16. Zhang W, Duan S, Bleibel WK, et al. Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet. 2009;125(1):81-93.
17. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575.
18. Hoffman MM, Buske OJ, Wang J, Weng Z, Bilmes JA, Noble WS. Unsupervised pattern discovery in human chromatin structure through genomic segmentation. Nat Methods. 2012;9(5):473-476.
19. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res. 2011;39(database issue): D1171-D1176.
20. Shimada M, Miyagawa T, Kawashima M, et al. An approach based on a genome-wide association study reveals candidate loci for narcolepsy. Hum Genet. 2010;128(4):433-441.
21. Hinds DA, McMahon G, Kiefer AK, et al. A genome-wide association meta-analysis of selfreported allergy identifies shared and allergyspecific susceptibility loci. Nat Genet. 2013;45(8): 907-911.
22. Bailey SD, Xie C, Do R, et al; DREAM investigators. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care. 2010;33(10): 2250-2253.
23. Miyagawa T, Toyoda H, Hirataka A, et al. New susceptibility variants to narcolepsy identified in HLA class II region. Hum Mol Genet. 2015;24(3): 891-898.
24. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707-747.
25. Xanthoudakis S, Viola JP, Shaw KT, et al. An enhanced immune response in mice lacking the transcription factor NFAT1. Science. 1996; 272(5263):892-895.
26. Karwot R, Übel C, Bopp T, Schmitt E, Finotto S. Increased immunosuppressive function of CD4(1)CD25(1)Foxp3(1)GITR1 T regulatory cells from NFATc2((-/-)) mice controls allergeninduced experimental asthma. Immunobiology. 2012;217(9):905-911.
27. Nagamoto-Combs K, Combs CK. Microglial phenotype is regulated by activity of the transcription factor, NFAT (nuclear factor of activated T cells). J Neurosci. 2010;30(28): 9641-9646.
28. Choi JM, Sohn JH, Park TY, Park JW, Lee SK. Cell permeable NFAT inhibitory peptide Sim-2-VIVIT inhibits T-cell activation and alleviates allergic airway inflammation and hyper responsiveness. Immunol Lett. 2012;143(2): 170-176.
29. Elloumi HZ, Maharshak N, Rao KN, et al. A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis. PLoS ONE. 2012;7(3): e34172.
30. Noguchi H, Matsushita M, Okitsu T, et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med. 2004;10(3):305-309.
31. Kuriyama M, Matsushita M, Tateishi A, et al. A cell-permeable NFAT inhibitor peptide prevents pressure-overload cardiac hypertrophy. Chem Biol Drug Des. 2006;67(3):238-243.
32. Zhang S, Luo L, Wang Y, Gomez MF, Thorlacius H. Nuclear factor of activated T cells regulates neutrophil recruitment, systemic inflammation, and T-cell dysfunction in abdominal sepsis. Infect Immun. 2014;82(8):3275-3288.
33. Roberts I, Izraeli S. Haematopoietic development and leukaemia in Down syndrome. Br J Haematol. 2014;167(5):587-599.
34. Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature. 2006; 441(7093):595-600.
35. Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol. 2009;156(2):189-193.